12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RG7597: Phase II started

Roche disclosed in its 3Q12 earnings that it began the Phase II MEHGAN trial to compare RG7597 vs. cetuximab in 110 patients. ImClone Systems Inc., a...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >